Miscellaneous
Hear a 5-minute summary of a retrospective study investigating whether GLP-1 receptor agonists might affect the development of glaucoma in people with diabetes, published in the British Journal of Ophthalmology. Listen for a quick overview of the key findings. References: Publication: Sterling J, et al. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2021 Aug 19:bjophthalmol-2021-319232. Epub ahead of print. Additional references: Zhao YX, Chen XW. Diabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studies. Int J Ophthalmol. 2017 Sep 18;10(9):1430-1435. Sterling JK, et al. GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension. Cell Rep. 2020 Nov 3;33(5):108271. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. Funding statement: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.